Type 2 diabetes is a chronic condition characterized by insulin resistance, influenced by genetics, obesity, and lifestyle factors. Fenugreek, rich in bioactive compounds, has shown promise in diabetes care due to its hypoglycemic and anti-inflammatory properties. Advanced techniques like Gas Chromatography-Mass Spectrometry (GC-MS) aid in detecting bioactive substances, helping refine therapeutic applications.
Fenugreek leaves were processed for phytochemical analysis, revealing compounds such as Squalene, Phytol, and Azelaic acid. In-vitro studies focused on ?-amylase inhibition to assess glucose regulation potential, while in-silico docking examined ligand-protein interactions to evaluate therapeutic efficacy. Using PyRx and Discovery Studio, computational studies validated Fenugreek’s potential as an antidiabetic agent. ADMET analyses with Swiss ADME and ADMET LAB 2 predicted pharmacokinetics and toxicity, confirming the compounds’ drug-likeness and metabolic stability.
These findings highlight Fenugreek’s therapeutic value in managing Type 2 diabetes. The combined use of biochemical assays and computational methods underscores its potential to regulate glucose metabolism and mitigate postprandial hyperglycemia, paving the way for further research into its clinical applicability.
International Journal of Pharmacognosy and Life Science
